Betsy O’Donnell, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of topics from Day 1 of the 2023 Best of Hematology Conference. Dr O’Donnell discusses the triplet regimen of acalabrutinib, venetoclax, and obinutuzumab in patients with high-risk CLL. Dr O’Donnell also discusses multiple myeloma and anti-BCMA CAR T-cell therapies.